DOI: 10.25881/BPNMSC.2019.31.76.021


Bocharov A.V.1, Popov L.V.2

1 Kostroma Regional Clinical Hospital named after Korolev E.I., Kostroma

2 Federal State Public Institution «National Medical and Surgical Center named after N.I. Pirogov» of the Ministry of Healthcare of the Russian Federation Moscow


the literature review considers the main stages of the evolution of drug-eluting stents, the largest randomized clinical trials comparing the immediate and long-term results of coronary artery bypass grafting and percutaneous coronary angioplasty in patients with coronary heart disease. It also shows the change of criteria for revascularization of the coronary channel.

Keywords: coronary heart disease, coronary artery bypass grafting, stenting of coronary arteries, drug-eluting stent, revascularization of the coronary channel.


1. Albiero, R., Adamian, M., Kobayashi, N., Amato, A., Vaghetti, M., Di Mario, C., Colombo, A. Short- and intermediate-term results of (32)P radioactive beta-emitting stent implantation in patients with coronary artery disease: the Milan dose-response study. // Circulation. – 2000. – Vol. 101(1) – P. 18–26.

2. Chesebro, J.H., Fuster, V. Platelet inhibitors in coronary artery bypass operations. // N.Engl. J. Med. – 1982. – Vol. 307. – P. 1453–1454.

3. Chesebro, J.H., Fuster, V., Elvaback, L.R. Effect of dipyridamole and aspirin on late vein graft patency after coronary bypass operation. // N. Engl. J. Med. – 1984. – Vol. 310. – P. 209–214.

4. Chevalier, B., Silber, S., Park, S.-J Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Libertе Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries. // Circ. Cardiovasc. Interv. – 2009. – Vol. 2(3). – P. 188–195.

5. Colombo, A., Godino, C., Donahue, M. One-year clinical outcome of amphilimus polymer-free drug-eluting stent in diabetes mellitus patients. Insight from the ASTUTE registry (Amphilimus iTalian mUlticenTre rEgistry). // Intern. J. Cardiol. – 2016. – Vol. 214. – P. 113–120.

6. Cosgrave, J., Corbett, S.J., Melzi, G., Babic, R., Biondi-Zoccai, G.G., Airoldi, F., Chieffo, A., Sangiorgi, G.M., Montorfano, M., Michev, I., Carlino, M., Colombo, A. Late restenosis following sirolimus-eluting stent implantation. // Am. J. Cardiol. – 2007. – Vol. 100(1). – P. 41–44.

7. Ellis, S.G. Everolimus-eluting bioresorbable vascular scaffolds in patients with coronary artery disease: ABSORB III trial 2-year results. TCTMD. // URL. March 19, 2017.

8. Farkouh, M.E., Domanski, M., Sleeper, L.A., et al. Strategies for multivessel revascularization in patients with diabetes. // N. Engl. J. Med. – 2012. – Vol. 367 (25). – P. 2375–2384.

9. Fath-Ordoubadi, F. One year clinical outcomes in patients with acute myocardial infarction treated with a new generation DES: NOBORI AMI study Manchester Royal Infirmary, Manchester, United Kingdom. Present- ed at Euro PCR-2010, Paris, France.

10. Gao, R., Yang, Y., Han, Y. et al. ABSORB China Investigators. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. // J. Am. Coll. Cardiol. – 2015. – Vol. 66. – P. 2298–2309.

11. Grube, E., Sonoda, S., Ikeno, F., et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. // Circulation. – 2004. – Vol. 109(18). – P. 2168–2171.

12. Kasaoka, S., Tobis, J.M., Akiyama, T., Reimers, B., Di Mario, C., Wong, N.D., Colombo, A. Angiographic and intravascular ultrasound predictors of in-stent restenosis. // J. Am. Coll. Cardiol. – 1998. – Vol. 32(6) – P. 1630–1635.

13. Kimura, T., Kozuma, K., Tanabe, K. et al. ABSORB Japan Investigators. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB // Japan. Eur. Heart J. – 2015. – Vol. 36. – P. 3332–3342.

14. Leon, M.B., Teirstein, P.S., Moses, J.W., Tripuraneni, P., Lansky, A.J., Jani, S., Wong, S.C., Fish, D., Ellis, S., Holmes, D.R., Kerieakes D., Kuntz, R.E. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. // N. Engl. J. Med. – 2001. – Vol. 344(4) – P. 250–256.

15. McFadden, E.P., Stabile, E., Regar, E., Cheneau, E., Ong, A.T., Kinnaird, T., Suddath, W.O., Weissman, N.J., Torguson, R., Kent, K.M., Pichard, A.D., Satler, L.F., Waksman, R., Serruys, P.W. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. // Lancet. – 2004. – Vol. 364(9444). – P. 1519–1521.

16. Mohr, F.W., Morice, M.C., Kappetein, A.P., Feldman, T.E., Ståhle, E., Colombo, A., Mack, M.J., Holmes, Jr., Morel, M.A., Van Dyck, N., Houle, V.M., Dawkins, K.D., Serruys, P.W. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. // Lancet. – 2013. – Vol. 381(9867). – P. 629–638.

17. Morice, M.C., Serruys, P.W., Sousa, J.E., Fajadet, J., Ban Hayashi, E., Perin, M., Colombo, A., Schuler, G., Barragan, P., Guagliumi, G., Molnàr, F., Falotico R., RAVEL Study Group. Randomized study with the sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. // N. Engl. J. Med. – 2002. – Vol. 346(23). – P. 1773–1780.

18. Moses, J.W., Leon, M.B., Popma, J.J., Fitzgerald, P.J., Holmes, D.R., O’Shaughnessy, C., Caputo, R.P., Kereiakes, D.J., Williams, D.O., Teirstein, P.S., Jaeger, J.L., Kuntz, R.E., SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. // N. Engl. J. Med. – 2003. – Vol. 349(14) – P. 1315–1323.

19. Naber, C.K., Urban, P., Ong, P.J. et al. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome% a Leaders Free ACS sub-study. // Eur. Heart J. – 2017. – Vol. 38(13). – P. 961–969.

20. Nikolsky, E., Lansky, A.J., Sudhir, K. et al. SPIRIT IV trial design: A large-scale randomized comparison of everolimus- eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. // Am. Heart J. – 2009. – Vol.158. – P. 520–526.

21. Pandya, B., Gaddam, S., Raza, M. et al. Biodegdable polymer stents versus second generation drug elutingstents: A meta-analysis and systematic review of randomized controlled trials. // World J. Cardiol. – 2016. – Vol. 8. – P. 240–246.

22. Puskas, J.D., Pawale, A., Sharma, S.K. Hybrid coronary revascularization. A new treatment paradigm for selected patients with multivessel coronary artery disease. // JACC. – 2014. – Vol. 7(10). – P. 1284–1286.

23. Romaguera, R., Gomez-Hospital, J.A., Comez-Lara, J. et al. A randomized comparsion of reservoir-based polymer-free amphilimus-eluting stents with durable polymer in patients with diabetes mellitus. The RESERVOIR clinical trial. // JACC. – 2016. – Vol. 9(1). – P. 42–50.

24. Serruys, P., AT, O., Piek, J.J., et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. // Euro. Intervention. – 2005. – Vol. 1. – P. 58–65.

25. Serruys, P.W., Chevalier, B., Sotomi, Y. et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. // Lancet. – 2016. – Vol. 388. – P. 2479–2491.

26. Serruys, P.W., Morice, M.C., Kappetein, A.P., et al. Percutaneous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease. // N. Engl. J. Med. – 2009. – Vol 360. – P. 961–972.

27. Serruys, P.W., Ruygrok, P.J.N.., Pier, J.J., et al. A randomized comparison of an everolimus eluting coronary stent with a paclitaxel eluting coronary stent: the SPIRIT II trial. // Euro Intervention. – 2006. – Vol. 2. – P. 286–294.

28. Stettler, C., Allemann, S., Wandel, S., Kastrati, A., Morice, M.C., Schomig, A., Pfisterer, M.E., Stone, G.W., Leon, M.B., de Lezo, J.S., Goy, J.J., Park, S.J., Sabate, M., Suttorp, M.J., Kelbaek, H., Spaulding, C., Menichelli, M., Vermeersch, P., Dirksen, M.T., Cervinka, P., De Carlo, M., Erglis, A., Chechi, T., Ortolani, P., Schalij, M.J., Diem, P., Meier, B., Windecker, S., Juni, P. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. // BMJ. – 2008. – Vol. 337 – P. 1331.

29. Stone, G.W., Sabik, J.F., Serruys, P.W., Simonton, C.A., Généreux, P., Puskas, J. et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. // N. Engl. J. Med. – 2016. – Vol. 375(23). – P. 2223–2235.

30. Stone, G.W., Midei, M., Newman W. et al. (SPIRIT III Investigators). Comparison of an everolumus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. // JAMA. – 2008. – Vol. 299(16). – P. 1903–1913.

31. Ung Kim, Chan-Hee Lee, Jung-Hwan Jo et al. A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study. // J. Korean Med. Sci. – Vol. 28(11). – P. 1609–1614.

32. Zaher Fanari, Sandra A. Weiss, Wei Zhang, Seema S. Sonnad, William S. Weintraub. Short, Intermediate and long term outcomes of CABG vs. PCI with DES in Patients With Multivessel Coronary Artery Disease. Meta-Analysis of Six Randomized Controlled Trials. // Eur. J. Cardiovasc. Med. – 2014. – Vol. 3(1). – P. 382–389.

For citation

Bocharov A.V., Popov L.V. Comparing efficiency of stenting with the use of sents with a drug coating with aortocoronary shunting. Change of criteria of revascularization of the coronary bed. Bulletin of Pirogov National Medical & Surgical Center. 2019;14(1):116-119. (In Russ.)